Gastrointestinal Protection in Patients on Dual Antiplatelet Therapy

Introduction to Gastrointestinal Protection

• The American College of Cardiology recommends PPIs over H2 receptor antagonists like famotidine for gastrointestinal protection in patients on dual antiplatelet therapy (DAPT), especially for those with risk factors for GI bleeding 1

Patient Selection for PPI Therapy

• Patients with a history of prior upper GI bleeding, advanced age, concomitant use of anticoagulants, corticosteroids, NSAIDs, or H. pylori infection should receive PPI therapy 1
• The American Heart Association suggests that patients without these risk factors may consider H2RAs, such as famotidine, which has shown some efficacy in reducing gastroduodenal ulcers compared to placebo (3.8% vs 23.5%) 1

PPIs and Clopidogrel Interactions

• The American College of Cardiology notes that while some pharmacodynamic studies show PPIs (particularly omeprazole) may attenuate clopidogrel's antiplatelet effects, clinical outcome data have not shown significant increases in major adverse cardiovascular events with PPI co-therapy 2
• Consider pantoprazole rather than omeprazole when using a PPI with clopidogrel, as it has less CYP2C19 inhibition 2

Gastroprotection Administration and Errors

• Take PPIs 30 minutes before breakfast for optimal acid suppression, as recommended by medical guidelines 3
• Avoid cimetidine specifically when choosing an H2RA with clopidogrel, as it can competitively inhibit CYP2C19; other H2RAs are preferable 1
• Discontinuing antiplatelet therapy due to GI symptoms increases cardiovascular event risk; using appropriate gastroprotection helps maintain DAPT adherence 1